[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Candel Therapeutics Inc (CADL)

Candel Therapeutics Inc (CADL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 585,427
  • Shares Outstanding, K 73,270
  • Annual Sales, $ 0 K
  • Annual Income, $ -38,180 K
  • EBIT $ -56 M
  • EBITDA $ -56 M
  • 60-Month Beta -0.59
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.24

Options Overview Details

View History
  • Implied Volatility 135.29% (+27.19%)
  • Historical Volatility 98.01%
  • IV Percentile 37%
  • IV Rank 6.73%
  • IV High 970.42% on 02/17/26
  • IV Low 74.98% on 07/30/25
  • Expected Move (DTE 23) 1.49 (18.71%)
  • Put/Call Vol Ratio 0.27
  • Today's Volume 1,207
  • Volume Avg (30-Day) 897
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 6,964
  • Open Int (30-Day) 7,293
  • Expected Range 6.46 to 9.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.22
  • Number of Estimates 3
  • High Estimate $-0.16
  • Low Estimate $-0.26
  • Prior Year $-0.09
  • Growth Rate Est. (year over year) -144.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.11 +30.11%
on 05/01/26
9.27 -14.24%
on 05/14/26
+1.45 (+22.31%)
since 04/24/26
3-Month
4.44 +79.05%
on 03/30/26
9.27 -14.24%
on 05/14/26
+2.80 (+54.37%)
since 02/26/26
52-Week
4.35 +82.76%
on 11/25/25
9.27 -14.24%
on 05/14/26
+2.52 (+46.41%)
since 05/23/25

Most Recent Stories

More News
Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data

Candel Therapeutics (NASDAQ:CADL) Chief Executive Officer Dr. Paul Peter Tak said the company remains focused on advancing its viral immunotherapy programs following newly presented prostate cancer data...

CADL : 7.95 (-0.50%)
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting

Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in prostate...

CADL : 7.95 (-0.50%)
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026 Announced purpose-built...

CADL : 7.95 (-0.50%)
Candel Therapeutics to Present at Upcoming Investor Conferences

NEEDHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) --  Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies...

CADL : 7.95 (-0.50%)
Candel Therapeutics Reports Before Its Prostate Cancer Data Reveal—Or Is That the Other Way Around

Barchart Research What to Expect from CADL Earnings CADL Generated May 11, 2026 Current Price $8.85 EPS Estimate $$-0.22 Consensus Rating Moderate Buy Average Move 8.92% Candel Therapeutics Reports Before...

CADL : 7.95 (-0.50%)
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Conference Call Scheduled for Friday, May 15, 2026, at 1:00 PM ET NEEDHAM, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage...

CADL : 7.95 (-0.50%)
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological...

CADL : 7.95 (-0.50%)
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA submission in Q4 2026 NEEDHAM, Mass., April 29, 2026 (GLOBE...

CADL : 7.95 (-0.50%)
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological...

CADL : 7.95 (-0.50%)
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with aglatimagene...

CADL : 7.95 (-0.50%)

Business Summary

Candel Therapeutics Inc. is a late clinical stage biopharmaceutical company. It involved in developing novel oncolytic viral immunotherapies. The company's product pipeline includes CAN-2409 and CAN-3110. Candel Therapeutics Inc. is based in NEEDHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 8.53
2nd Resistance Point 8.42
1st Resistance Point 8.18
Last Price 7.95
1st Support Level 7.83
2nd Support Level 7.72
3rd Support Level 7.48

See More

52-Week High 9.27
Last Price 7.95
Fibonacci 61.8% 7.39
Fibonacci 50% 6.81
Fibonacci 38.2% 6.23
52-Week Low 4.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.